AnaptysBio's IPO

AnaptysBio raised a round of funding on January 26, 2017. Investors include Public.

AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. The compa…

Articles about AnaptysBio's IPO: